Efficacy of ketamine in the treatment of depressive disorder

Efficacy of add on trial of single or double dose of intravenousKetamine to usual treatment with mood stabilizers in treating bipolardepression

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20101130005280N58

Enrollment

Registered

2022-10-06

Start date

2022-10-25

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar depression. Bipolar disorder

Interventions

Intervention 1: Control group will receive normal saline. Intervention 2: Intervention group: Ketamine in dose of 0.5 milligram/kilogram will be infused over 40 minutes in case group.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients who have received a depressive episode by a doctor diagnosing bipolar disorder (one and two) In the last two weeks (since the start of sampling) there has been no significant change in their medication regimen

Exclusion criteria

Exclusion criteria: Patients with severe physical illness (especially hypertension) History of substance use and dependence in the past month

Design outcomes

Primary

Measure	Time frame
Depression. Timepoint: base line and 90 minutes, 1 day, 7 days, 30 days and 60 days after infusion. Method of measurement: Hamilton depression questionnaire.;Anxiety. Timepoint: base line and 90 minutes, 1 day, 7 days, 30 days and 60 days after infusion. Method of measurement: Beck anxiety scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Talaei

Mashhad University of Medical Sciences

pbsrc@mums.ac.ir+98 51 3711 2701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026